Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb This Week: Interpace Diagnostics, Exact Diagnostics, and PCRmax

Interpace Diagnostics PanDNA

Interpace Diagnostics has launched PanDNA, a new product that stratifies patients' risk of developing pancreatic cancer based on specific molecular criteria. PanDNA assigns risk for a cyst based on an accumulation of three molecular criteria: DNA quantity, an oncogene panel, and a tumor suppressor gene panel. If the product has a higher number of findings, it is an indication of a potentially higher risk of prognosis, the company said. The product is currently in the initial phase of launch, but Interpace said that it expects the final rollout to come on or around Oct. 15.

Exact Dx Zika Verification Panel and Zika Low and High Run Controls

Exact Diagnostics has launched its Zika Verification panel and Zika Low and High Run controls. The Zika panel consists of five panel members, ranging from 100 copies per milliliter to 1 million copies per milliliter. The Zika High and Low Run control are manufactured following ISO 17511 Helping ensure consistent results. Both of these products were created using the Zika strain PRVABC59, and are value assigned using digital PCR.

PCRmax Alpha Cycler 2

PCRmax, a subsidiary of Bibby Scientific, has launched its Alpha Cycler 2, a compact dual-block system for flexible and PCR-based DNA analysis with unique reporting and diagnostic function. The system is coupled with an Andriod OS interface, and a mobile app which lets users scan a QR code that allows them to monitor their runs and access programs remotely. The platform also saves laboratory space as it condenses two independent blocks into one compact system, the company said.

For more new products and services, please visit the New Products page on our website.